The Spillover Effects of Medicare Managed Care: Medicare Advantage and Hospital Utilization
---- Acknowledgements ----
The authors gratefully acknowledge grant funding from the National Institute on Aging (grant P01-AG032952) as well as invaluable assistance from Vanessa Azzone and insightful comments from Joe Newhouse, Tom McGuire, Mary Beth Landrum, and the P01 investigator team. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.
---- Disclosure of Financial Relationships for Katherine Baicker ----
Baicker is a Director of Eli Lilly. Baicker and Chernew serve on the Medicare Payment Advisory Commission. The views in this paper the authors' own, and do not reflect the views of any organization with which they are affiliated.
---- Disclosure of Financial Relationships for Michael Chernew ----
Consultant: Abbott, AstraZeneca, Bristol-Myers Squibb, Center for Medicare and Medicaid Services [CMS], GlaxoSmithKline, AHIP, VBIDHealth, National Pharmaceutical Council, Pfizer Inc., Precision Health Economics LLC, Truven, TriZetto, Eli Lilly, Mass Medical Society, AHA, Pfizer Inc., Boston Scientific, Humana, AHRQ, Lewin, Carefirst, Welvie